Thu. 14 Mar 2024, 4:36pm ET
Benzinga
Earnings, Earnings Beats, News
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $56.200 million which beat the analyst consensus estimate of $55.393 million by 1.46 percent. This is a 1.85 percent increase over sales of $55.180 million the same period last year.